Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Opioid-Induced Constipation Treatment Market Size From 2025 to 2034?
The market for treating opioid-induced constipation has significantly expanded in the past few years. Expected to surge from $1.78 billion in 2024 to $1.9 billion in 2025, it boasts a compound annual growth rate (CAGR) of 6.7%. Factors such as the growing number of elderly people, tailored OIC treatments, the presence of efficient OIC drugs, a rise in opioid use, and an increasing occurrence of gastrointestinal disorders have contributed to this historical growth.
In the forthcoming years, the market size of opioid-induced constipation treatment is predicted to witness a significant expansion. It is projected to balloon to$2.42 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. The market’s progress in the anticipated period can be linked to heightened drug approval drives, escalating usage of opioid analgesic prescriptions, skyrocketing R&D spendings for innovative treatments, and a surge in the development of biologics. Future market trends will be characterized by patient education and awareness, the advent of targeted therapies, non-pharmacological procedures, biotech breakthroughs, and augmented investment.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp
What Are the Core Market Drivers Propelling Growth in the Opioid-Induced Constipation Treatment Industry?
The expansion of the opioid-induced constipation treatment market is set to be fueled by the increasing use of opioids in treating both cancer-related and non-cancer-related pain. Herein, the pain related to cancer refers to discomfort directly attributable to cancer or its treatment, while non-cancer pain refers to discomfort arising from non-cancer conditions. The use of opioids for both cancer and non-cancer pain management is motivated by the need for effective handling of moderate to severe pain, taking into account factors such as pain intensity, duration, patient response to alternative treatments, and overarching objective of enhancing life quality while also mitigating potential addiction risks and side effects. Opioid-induced constipation (OIC) therapy assists patients suffering from cancer or non-cancer pain by mitigating constipation due to opioid utilization, enhancing overall comfort, compliance with pain management approaches, and life quality without impacting pain relief. For example, as per the Government of Canada, a Canada-based federal authority, there might be up to 8.3 million Canadians suffering from chronic pain by 2025, with figures potentially touching 9.0 million by 2030. Hence, the surge in opioid use for cancer and non-cancer pain signifies a growth driver for the opioid-induced constipation treatment market.
How Is the Opioid-Induced Constipation Treatment Market Segmented?
The opioid-induced constipation treatmentmarket covered in this report is segmented –
1) By Drug Class: Laxatives; Peripherally Acting μ-opioid Receptor Antagonists; Serotonin Receptor Agonists; Prostaglandin
2) By Type: Oral; Parenteral
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives; Stimulant Laxatives; Bulk-Forming Laxatives
2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol; Methylnaltrexone; Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride; Tegaserod
4) By Prostaglandin: Lubiprostone
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp
Which Regions Are Driving the Next Phase of the Opioid-Induced Constipation Treatment Market Growth?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Opioid-Induced Constipation Treatment Industry?
Leading businesses in the market for opioid-induced constipation treatment are forging strategic alliances to pioneer novel medications. These strategic collaborations benefit those in the opioid-induced constipation treatment market by pooling resources and knowledge, boosting research and development potentials, broadening market access, and speeding up the process of bringing products to market, which ultimately facilitates innovation and expansion in the industry. To exemplify, Kyowa Kirin Co. Ltd, a biotechnology firm from Japan, collaborated with Grünenthal GmbH, a pharmaceutical firm based in Germany, in November 2022 to amalgamate solutions for patients. The goal of this collaboration is to strengthen the growth and worldwide accessibility of a range of transformative pain management drugs, including treatments for opioid-induced constipation, breakthrough cancer pain and osteoporosis.
View the full report here:
How Is the Opioid-Induced Constipation Treatment Market Defined and What Are Its Core Parameters?
Opioid-induced constipation (OIC) treatment refers to the various approaches and medications used to manage constipation caused by the use of opioid medications. These treatments aim to alleviate the symptoms of constipation without compromising the pain-relieving effects of opioids, thereby improving the patient’s overall quality of life and maintaining effective pain management with both pharmacological with non-pharmacological approaches.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
